Pivotal readout

Alnylam's five-year HELIOS-B data favor starting vutrisiran early in ATTR-CM

Patients treated with Amvuttra throughout the extension had a 41% lower five-year risk of death or recurrent cardiovascular events than those who started roughly three years later. Those p-values were nominal, with no correction for multiple testing. A separate exploratory look at 48 patients found exercise capacity was preserved over two years compared with placebo.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Schematic animation of vutrisiran molecules travelling in the blood to the liver, binding receptors on a liver cell through their sugar tags, and inside the cell cutting transthyretin messenger RNA so that less transthyretin protein is released into the blood.
Vutrisiran: silencing transthyretin in the liver. Watch the mechanism animation on the vutrisiran page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call